Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The precise function of PARK2 is unknown\; however, the encoded protein is a component of a multiprotein E3 ubiquitin ligase complex that mediates the targeting of substrate proteins for proteasomal degradation. Additionally we are shipping PARK2 Kits (15) and PARK2 Proteins (9) and many more products for this protein.
Showing 10 out of 211 products:
Human Monoclonal PARK2 Primary Antibody for IF, WB - ABIN393540
Kägi, Klein, Wood, Schneider, Pramstaller, Tadic, Quinn, van de Warrenburg, Bhatia: Nonmotor symptoms in Parkin gene-related parkinsonism. in Movement disorders : official journal of the Movement Disorder Society 2010
Show all 5 references for ABIN393540
Human Polyclonal PARK2 Primary Antibody for EIA, IHC (p) - ABIN358990
Kumru, Santamaria, Tolosa, Valldeoriola, Muñoz, Marti, Iranzo: Rapid eye movement sleep behavior disorder in parkinsonism with parkin mutations. in Annals of neurology 2004
Show all 5 references for ABIN358990
Human Polyclonal PARK2 Primary Antibody for ICC, IF - ABIN407784
Eid, Ito, Otsuki: Triggering of Parkin Mitochondrial Translocation in Mitophagy: Implications for Liver Diseases. in Frontiers in pharmacology 2016
Show all 4 references for ABIN407784
Human Polyclonal PARK2 Primary Antibody for FACS, IF - ABIN390365
West, Kapatos, OFarrell, Gonzalez-de-Chavez, Chiu, Farrer, Maidment: N-myc regulates parkin expression. in The Journal of biological chemistry 2004
Show all 2 references for ABIN390365
Human Polyclonal PARK2 Primary Antibody for ELISA, WB - ABIN251684
La Cognata, Iemmolo, DAgata, Scuderi, Drago, Zappia, Cavallaro: Increasing the Coding Potential of Genomes Through Alternative Splicing: The Case of PARK2 Gene. in Current genomics 2014
Show all 2 references for ABIN251684
Human Polyclonal PARK2 Primary Antibody for EIA, WB - ABIN358989
Pigullo, De Luca, Barone, Marchese, Bellone, Colosimo, Scaglione, Martinelli, Di Maria, Pizzuti, Abbruzzese, Dallapiccola, Ajmar, Mandich: Mutational analysis of parkin gene by denaturing high-performance liquid chromatography (DHPLC) in essential tremor. in Parkinsonism & related disorders 2004
Show all 2 references for ABIN358989
Human Polyclonal PARK2 Primary Antibody for FACS, IF - ABIN390366
Wang, Denison, Lai, Philips, Montoya, Kock, Schüle, Klein, Shridhar, Roberts, Smith: Parkin gene alterations in hepatocellular carcinoma. in Genes, chromosomes & cancer 2004
Show all 2 references for ABIN390366
Human Polyclonal PARK2 Primary Antibody for WB - ABIN372698
Jenner, Dexter, Sian, Schapira, Marsden: Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. in Annals of neurology 1992
Parkin-dependent mitophagy suppresses neural neurodegeneration by removing damaged mitochondria.
We demonstrate here that vps35 (show vps35 Antibodies) genetically interacts with parkin
Clu (show CLU Antibodies) directly modulates mitochondrial function, and that Clu's function contributes to the PINK1 (show PINK1 Antibodies)-Park pathway of mitochondrial quality control.
Human Mask homolog ANKHD1 (show ANKHD1 Antibodies) may serve as a potential therapeutic target for treating Parkinson disease caused by pink1 (show PINK1 Antibodies)/parkin mutations.
These results indicate that the in vivo rescue is due to restoring CI activity rather than promoting mitophagy Our findings support the emerging view that PINK1 (show PINK1 Antibodies) plays a role in regulating CI activity separate from its role with Parkin in mitophagy
MUL1 (show MUL1 Antibodies) acts in parallel to the PINK1 (show PINK1 Antibodies)/parkin pathway on a shared target mitofusin (show MFN2 Antibodies) to maintain mitochondrial integrity.
Parkin cooperates with PINK1 to promote hnRNP-F/Glo ubiquitination and nRCC mRNA translation.
The loss-of-function mutation in parkin results in defective immune response against bacterial infection. Additionally, parkin mutant larvae showed hypersensitivity against wound regardless of bacterial infection.
data thus support the potential of folic acid in alleviating the behavioural defects, oxidative stress, augmentation of zinc and ATP levels in parkin knock down flies
Parkin phosphorylation by PINK1 (show PINK1 Antibodies) drives Parkin E3 activity. endogenous PINK1 (show PINK1 Antibodies) precisely controls Parkin activity to maintain the mitochondrial function in muscle tissue and the neuronal function in dopaminergic neurons.
The identification of PINK1 (show PINK1 Antibodies) and Parkin as suppressors of an immune-response-eliciting pathway provoked by inflammation suggests new insights into Parkinson's disease pathology.
p62 (show GTF2H1 Antibodies) are subjected to parkin mediated proteasomal degradation
A comprehensive analysis of influence of the Parkinson disease-associated genes Parkin and DJ-1 (show PARK7 Antibodies) on neurotransmitter receptor (show GRIN1 Antibodies) expression in mice
Whereas Parkin has been reported to positively regulate the expression of OPA1 (show MED12 Antibodies) through NEMO (show IKBKG Antibodies), herein we found that PARK2 overexpression did not modify the expression of OPA1 (show MED12 Antibodies).
In mouse hearts Parkin functions as a stress-induced and developmentally-programmed facilitator of cardiomyocyte mitochondrial turnover. (Review)
findings support the notion that BAG2 (show BAG2 Antibodies) is an upstream regulator of the PINK1 (show PINK1 Antibodies)/PARKIN signaling pathway.
The PINK1 (show PINK1 Antibodies)-Parkin pathway is activated in response to metabolic stress
Overexpressed human wild type alpha-synuclein (show SNCA Antibodies) in the substantia nigra was phosphorylated at Ser (show SIGLEC1 Antibodies) 129 significantly more in parkin knockout mice, though the total alpha synuclein (show SNCA Antibodies) levels were the same as in wild type mice.
analysis of two types of mitophagy, a DNM1L (show DNM1L Antibodies)-dependent pathway and a PARK2-dependent pathway
FBXW8 (show FBXW8 Antibodies) and PARK2 are sequestrated into insolubility by ATXN2 (show ATXN2 Antibodies) PolyQ expansions, but only FBXW8 (show FBXW8 Antibodies) expression is dysregulated
Patients with Parkin compound heterozygous mutations have relatively preserved olfaction compared to Parkin single heterozygotes and non-carriers
This study showed that LRRK2 (show LRRK2 Antibodies), PARK2 and ATP13A2 (show ATP13A2 Antibodies) are under copy number variations influence in patient with Parkinson disease.
Our results using the multivariate analysis between the additive and dominant model demonstrated that tag SNP rs2803073 of PARK2 is associated with susceptibility to epithelial ovarian cancer (p = 0.018, OR = 0.42).
Exonic duplication might result in a more severe interference of PARK2 expression and the clinical feature than deletion at the A region (exons 2-4) of the PARK2 locus.
parkin influences the spatial organization of actin filaments, the shape of human fibroblasts, and their elastic response to an external applied force
this study results may reveal a unique genetic-environmental interactions contributing to the disease mechanism of a PD patient carrying Ex5del in PARK2
Pedigree of Parkinson's disease family indicating consanguineous marriages as well as two sequence variants identified in the Parkin gene
assessed two sisters with PARK2 early-onset Parkinson's disease confirmed on genetic testing. Both sisters demonstrated a compound heterozygous missense mutation on exon 7
Impairment in mitophagy has been proven to be due to diminished PARK2 and insufficient vesicle induction, accumulating depolarized mitochondria and PINK1 (show PINK1 Antibodies).
Ubiquitylation of PKM2 by parkin does not affect its stability but decreases its enzymatic activity.
Single nucleotide polymorphism (SNP) analysis revealed seven SNPs in the porcine PARK2 gene, one missense and one silent mutation in exon 7 and five SNPs in intron 7
The precise function of this gene is unknown\; however, the encoded protein is a component of a multiprotein E3 ubiquitin ligase complex that mediates the targeting of substrate proteins for proteasomal degradation. Mutations in this gene are known to cause Parkinson disease and autosomal recessive juvenile Parkinson disease. Alternative splicing of this gene produces multiple transcript variants encoding distinct isoforms. Additional splice variants of this gene have been described but currently lack transcript support.
, E3 ubiquitin-protein ligase parkin
, Parkinson disease (autosomal recessive, juvenile) 2, parkin
, parkin protein
, parkin variant SV5DEL
, parkinson juvenile disease protein 2